e-Drug3D

1576

CABOZANTINIB

INN
CABOZANTINIB

cas 849217-68-1

CLASS

ANTINEOPLASTIC
TREATMENT OF PATIENTS WITH PROGRESSIVE METASTATIC MEDULLARY THYROID CANCER
INHIBITOR OF TYROSINE KINASE

ROUTE (list)

ORAL

ATC code

L01EX07

PK parameters

VD 349 LITER
Cl 4.4 LITER / HOUR
PPB 99.7 PERCENT
t1/2 55 HOUR

Solubility

PRACTICALLY INSOLUBLE IN AQUEOUS MEDIA

Target

TARGET RET
MET
VEGFR-1
VEGFR-2
VEGFR-3
KIT
TRKB
FLT-3
AXL
TIE-2

DrugCentral

Mast,stem cell growth factor receptor Kit UNIPROT P10721 KIT

Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3

Download SDF file

1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-

Formula:
C28H24FN3O5

Calculated chemical properties:

MW 501.50
NB_atoms 37
XLogP 5.54
PSA 95.385
NB_HD 2
NB_HA 8
fsp3 0.18
Lipinski(0=no;1=yes) 0

FDA
NDA 203756 (label) INN (CABOZANTINIB S-MALATE) COMETRIQ (EXELIXIS) APPROVAL= AP YEAR= 2012
NDA 208692 (label) INN (CABOZANTINIB S-MALATE) CABOMETYX (EXELIXIS INC) APPROVAL= AP YEAR= 2016
NDA 215942 (pdf not found) INN (CABOZANTINIB) CABOZANTINIB (TEVA PHARMS INC) APPROVAL= TA YEAR= 2022
NDA 213878 (pdf not found) INN (CABOZANTINIB) CABOZANTINIB (MSN LABORATORIES PRIVATE LTD) APPROVAL= TA YEAR= 2025